This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC.
RECOMMENDATIONS CHAPTER 1: DIAGNOSIS AND CLASSIFICATION OF THE MEASUREMENT OF BP FOR HDPs
A. There is good evidence to recommend the clinical preventive action II-1: Evidence from well-designed controlled trials without randomization B. There is fair evidence to recommend the clinical preventive action II-2: Evidence from well-designed cohort (prospective or retrospective) or case-control studies, preferably from more than one centre or research group C. The existing evidence is conflicting and does not allow to make a recommendation for or against use of the clinical preventive action; however, other factors may influence decision-making II-3: Evidence obtained from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category D. There is fair evidence to recommend against the clinical preventive action E. There is good evidence to recommend against the clinical preventive action III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees L. There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making *The quality of evidence reported in these guidelines has been adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on Preventive Health Care. 39 H ypertensive disorders of pregnancy remain leading causes of maternal and perinatal morbidity and mortality. 1, 2 The guideline summarized here assesses the quality of the relevant existing evidence and provides a reasonable approach to the diagnosis, evaluation, and treatment of the HDP, focusing on Canadian context.
Our purpose is to support evidence-based maternity care of women who are planning pregnancy and are at risk of an HDP, have an HDP in the current pregnancy, or are postpartum and had an HDP. When necessary, we have provided expert opinion about reasonable clinical care. Our health intent and aim is to improve short-and longterm maternal, perinatal, and paediatric outcomes and the cost-effectiveness of related interventions in pregnancies complicated by an HDP. The expected benefit of this guideline is improved outcomes for mother, baby, and child through evidence-advised practice. Our target users are multidisciplinary maternity care providers from primary to tertiary levels of health care.
The questions that this guideline seeks to address are:
• How, and in what setting, should BP be measured in pregnancy, and what is an abnormal BP?
• How should proteinuria be measured in pregnancy? What constitutes significant proteinuria? Is heavy proteinuria an indication for delivery?
• How should the HDPs be diagnosed and classified? What constitutes severe preeclampsia?
• What are the prognoses of pregnancies complicated by pre-existing hypertension, gestational hypertension, or preeclampsia?
• How can preeclampsia and its complications be predicted and/or prevented by lifestyle changes, medication, and/or care of a specific type or in a specific location?
• How should women with an HDP be managed regarding initial investigations, dietary and lifestyle changes, place of care, antihypertensive therapy, aspects of care specific to women with preeclampsia (such as magnesium sulphate), mode and timing of delivery, intrapartum care (including BP monitoring and analgesia/anaesthesia), and postpartum monitoring, treatment, and counselling regarding the impact of an HDP on both future pregnancy outcomes and longterm maternal and paediatric outcomes?
• What is the patient's perspective on her diagnosis and evaluation?
• 
Definition of Preeclampsia
Preeclampsia is most commonly defined by new-onset proteinuria and, potentially, other end-organ dysfunction. Hypertension and proteinuria are discussed above under "Diagnosis of Hypertension"' and "Management of Proteinuria." Women with preeclampsia may have a diminished, or no, nocturnal BP decrease. 4 Maternal end-organ dysfunction and fetal manifestations of preeclampsia illustrated in the Figure are all non-specific. In this model of its origins we describe preeclampsia that arises primarily through imperfect placentation (earlyonset or "placental" preeclampsia [pink]) or through either a lowered maternal threshold or excessive physiological placentation (late-onset or "maternal" preeclampsia [blue]). Some aspects of the preeclampsia process are specific to it, while others are shared with normotensive IUGR. A lowered maternal threshold may also influence the development of early-onset preeclampsia through With evidence of preeclampsia This is also known as superimposed preeclampsia, and is defined by the development of one or more of the following at ≥ 20 weeks:
• resistant hypertension, or
• new or worsening proteinuria, or
• one or more adverse conditions,* or • one or more severe complications.* Severe preeclampsia is defined as preeclampsia with one or more severe complications.
Gestational hypertension
This is defined as hypertension that develops for the first time at ≥ 20+0 weeks' gestation.
With comorbid condition(s) Comorbid conditions (e.g., pre-gestational type I or II diabetes mellitus or kidney disease) warrant tighter BP control outside of pregnancy because of their association with heightened cardiovascular risk.
With evidence of preeclampsia Evidence of preeclampsia may appear only many weeks after the onset of gestational hypertension.
Preeclampsia is defined as gestational hypertension with one or more of the following:
• new proteinuria, or
Preeclampsia
Preeclampsia may arise de novo. It is defined as gestational hypertension with one or more of the following:
Other hypertensive effects †
Transient hypertensive effect Elevated BP may be due to environmental stimuli, e.g., the pain of labour.
White-coat hypertensive effect
This is defined as BP that is elevated in the office (sBP ≥ 140 mmHg or dBP ≥ 90 mmHg), but consistently normal outside of the office (< 135/85 mmHg) by ABPM or HBPM Masked hypertensive effect This is defined as BP that is consistently normal in the office (sBP < 140 mmHg or dBP < 90 mmHg), but elevated outside of the office (≥ 135/85 mmHg) by ABPM or repeated HBPM. sBP: systolic BP; dBP diastolic BP; ABPM: ambulatory BP monitoring; HBPM: home BP monitoring *Adverse conditions and severe complications of preeclampsia are defined in Table 3 . †These may occur in women whose BP is elevated at < 20+0 or ≥ 20+0 weeks who are suspected of having pre-existing or gestational hypertension/ preeclampsia, respectively.
direct endothelial cell activation. The consequences of endothelial cell activation that appear consistent between all women with preeclampsia include a variable impact on multiple vulnerable organ systems. Disease severity generally correlates with the degree and number of organ dysfunctions. Fetal manifestations may occur before, with, or in the absence of maternal manifestations. 5 Table 3 outlines the end-organ dysfunctions of preeclampsia: adverse conditions and severe complications. Adverse conditions consist of maternal symptoms, signs, and abnormal laboratory results, and abnormal fetal monitoring results that may herald the development of severe maternal or fetal complications (including stillbirth). The adverse conditions are those that we wait for and respond to (e.g., low oxygen saturation) in an effort to avoid entirely the severe complications (e.g., pulmonary edema). That response could be more intensive maternal or fetal monitoring, specific treatment, or delivery. Severe maternal complications of preeclampsia warrant delivery.
The adverse conditions are manifestations of preeclampsia that increase the risk of adverse maternal or perinatal outcomes. 6 Table 3 lists the adverse conditions by maternal organ system. Of particular importance are preterm preeclampsia, chest pain or dyspnea, and abnormality of one or more of oxygen saturation by pulse oximetry, platelet count, serum creatinine, or aspartate transaminase. 6 Proteinuria predicts neither short-term adverse outcomes nor long-term maternal renal prognosis. 7, 8 HELLP syndrome is represented by its component parts (hemolysis, elevated liver enzymes, and low platelets), to which we react to by initiating delivery.
How maternal adverse conditions may predict fetal or neonatal outcomes in preeclampsia is unclear. The perinatal literature suggests that abnormal fetal monitoring of various types may identify increased fetal risk. The biophysical profile has unproven utility in high risk women, 9, 10 and may falsely reassure with early-onset IUGR 11 The origins and consequences of preeclampsia preeclampsia. Most experts suggest a combination of tests, with emphasis on umbilical artery Doppler when there is IUGR. 9
Other non-specific risk factors for severe complications of preeclampsia are immigrant status, young maternal age, nulliparity, lower maternal weight, and in the index pregnancy, multiple pregnancy and early-onset preeclampsia. 13 Definitions of severe preeclampsia vary, but most include multi-organ involvement [14] [15] [16] We modified our definition of severe preeclampsia to preeclampsia associated with one or more severe complications. Severe preeclampsia now warrants delivery regardless of gestational age. Our definition excludes heavy proteinuria and HELLP syndrome, which are not absolute indications for delivery, and includes stroke 17 and pulmonary edema, which are leading causes of maternal death in preeclampsia. 2
Other
A transient hypertensive effect is not associated with an increased risk of adverse outcomes. White-coat effect in early pregnancy (~30%) is common. 18 Forty percent of women progress to persistent hypertension at ≥ 20 weeks (i.e., gestational hypertension) and 8% to preeclampsia. Women with white-coat effect have risks (e.g., severe hypertension, preterm delivery, and NICU admission) intermediate between normotension and either preexisting or gestational hypertension. [19] [20] [21] [22] [23] [24] Masked hypertension in early pregnancy (~30%) is also common, 18 but associated perinatal risks are unknown. Outcomes with masked hypertension at ≥ 20 weeks (~10%) equate to those of gestational hypertension. 25, 26 Masked hypertension could be considered (and ambulatory or home BP monitoring performed) if there are unexplained maternal or perinatal complications typically associated with the HDPs. 36 . There is insufficient evidence to recommend use of the biophysical profile as part of a schedule of fetal testing in women with a hypertensive disorder of pregnancy. (II-2L) 37. If initial testing is reassuring, but there is ongoing concern about preeclampsia (e.g., change in maternal and/or fetal condition), maternal and fetal testing should be repeated. (III-C)
Comments
Most abnormalities found in maternal and fetal testing are non-specific. When preeclampsia is suspected, interpretation relies on findings of multiple (not single) abnormalities.
Preeclampsia imitators share manifestations with preeclampsia, but require different treatment. [27] [28] [29] [30] [31] (Table 5 ) We based our recommendations on the need to prevent preeclampsia and/or its associated complications. Pregnant women are classified as being at either low or increased risk of preeclampsia, usually by the presence of one or more of the risk markers in Table 6 (see Predicting Preeclampsia).
Preventative interventions may be best started before 16 weeks' gestation when most of the physiologic transformation of uterine spiral arteries occurs. Such early intervention has the greatest potential to decrease early forms of preeclampsia. 32 Women at low risk of preeclampsia have usually been from unselected populations of nulliparous and multiparous women. 46. There is insufficient evidence to make a recommendation about a heart-healthy diet (II-2L); workload or stress reduction (including bedrest) (II-2L); supplementation with iron with or without folate (I-L); vitamin D (I-L); pyridoxine (I-L); or food rich in flavonoids. (I-L)
Preventing Preeclampsia and its Complications in Women at Increased Risk
Women at increased risk of preeclampsia are most commonly identified by a personal or family history of an HDP, chronic medical disease, and/or abnormal uterine artery Doppler before 24 weeks' gestation. Combining clinical, biochemical, and/or ultrasonographic risk markers may better identify women at increased preeclampsia risk (see "Prediction"); however, no intervention trial has used such an approach to evaluate preventative therapy. 33, 34 Recommendations 47. Low-dose acetylsalicylic acid and calcium supplementation (of at least 1 g/d) for women with low calcium intake are recommended for preventions of preeclampsia in women at high risk. women with any HDP, ongoing salt restriction among women with pre-existing hypertension, heart-healthy diet, and calorie restriction for obese women. (III-L) 56. There is insufficient evidence to make a recommendation about the usefulness of exercise, workload reduction, or stress reduction. (III-L) 57. For women with gestational hypertension (without preeclampsia), some bed rest in hospital (vs. unrestricted activity at home) may be useful to decrease severe hypertension and preterm birth. (I-B) 58. For women with preeclampsia who are hospitalized, strict bed rest is not recommended. (I-D) 59. For all other women with an HDP, the evidence is insufficient to make a recommendation about the usefulness of some bed rest, which may nevertheless be advised based on practical considerations. (III-C)
The following recommendations apply to women with either pre-existing or gestational hypertension. 
Place of

Comments
When administered at ≤ 34+6 weeks' gestation, antenatal corticosteroids accelerate fetal pulmonary maturity and decrease neonatal mortality and morbidity, including among women with HDPs. 35 RCTs that administered steroids at 33+0 to 34+6 weeks resulted in reduced neonatal RDS. 35 Prior to elective Caesarean section at ≤ 38+6 weeks' gestation, antenatal corticosteroids decrease the excess neonatal respiratory morbidity and NICU admissions. 36, 37 All subgroup analyses have not necessarily revealed such benefits following Caesarean or vaginal delivery. 35
Timing of Delivery for Women With Preeclampsia
Delivery is the only intervention that initiates resolution of preeclampsia, and women with gestational hypertension or pre-existing hypertension may develop preeclampsia.
Recommendations
Consultation with an obstetrician (by telephone
if necessary) is mandatory in women with severe preeclampsia. (III-B) 82. All women with severe preeclampsia should be delivered immediately (either vaginally or by Caesarean), regardless of gestational age. (III-C) 83. For women with non-severe preeclampsia at < 24+0 weeks' gestation, counselling should include, as an option, information about delivery within days. (II-2B) 84. For women with non-severe preeclampsia at 24+0 to 33+6 weeks' gestation, expectant management 140. There should be confirmation that end-organ dysfunction of preeclampsia has resolved. (III-C) 141. Non-steroidal anti-inflammatory drugs should not be given postpartum if hypertension is difficult to control, there is evidence of kidney injury (oliguria and/or creatinine≥ 90 µM), or platelets are < 50 to 10 The Appendix ( Table 10 in the full document 3 ) lists tools to support the application of this guideline. Some websites provide general information about BP measurement for non-pregnant patients, but the recommendations are similar enough to those for pregnant women to be useful. Patients, their partners, and their care providers should be well educated about the HDP, and relevant sites are listed.
Implementation of any evidence depends on individual knowledge and beliefs, as well as institutional culture. Strong recommendations should be incorporated into clinical practice. In well-resourced settings, almost all preeclampsiarelated maternal deaths involve substandard care. 38 Some updates to the 2008 SOGC guidelines on the HDP may require additional effort to implement.
Recommendation 9 states that all measurement devices used in hospitals or offices should be checked regularly against a calibrated device may not be possible for all Canadian hospitals and offices to do on a regular basis.
Physicians should consider the category "other HDP" (white-coat and masked hypertension) as part of the classification of hypertensive women and consider using some form of out-of-office BP measurement to evaluate women with non-severe pre-existing or gestational hypertension.
Health care providers should inform pregnant women about the symptoms and signs of the HDPs and refer them to appropriate knowledge translation tools.
We recommend the use of corticosteroids for women ≤ 34+6 weeks' gestation who are at high risk of delivery within the next seven days. This gestational age cut-off represents a fundamental change in practice that will require discussion.
Physicians should be familiar with the blood bank policies of their own hospital.
Physicians should be aware of postpartum signs of maternal posttraumatic stress disorder and the maternal and perinatal long-term effects of HDPs, especially at this vulnerable time in maternal care when the maternity care provider is often handing back care to the primary care physician.
The reader is reminded to refer to the full open-access guideline published in Pregnancy Hypertension, 3 which contains not only the recommendations and tables presented here, but also all explanatory text and additional references.
